Stay updated on Nivolumab and Axitinib in RCC Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and Axitinib in RCC Clinical Trial page.

Latest updates to the Nivolumab and Axitinib in RCC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedRevision: v3.3.4 replaces v3.3.3 in the study documents section, with no changes to core study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check30 days agoChange DetectedLocations section consolidated under a single Locations heading, listing Maryland, New York, and Pennsylvania. Previous separate subsections for Maryland Locations, New York Locations, and Pennsylvania Locations were removed.SummaryDifference0.4%

- Check58 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check65 days agoChange DetectedThe government funding lapse notice about NIH operating status was removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check80 days agoChange DetectedThe Study Record Dates section now includes additional update timestamps (e.g., 2025-10-29, 2026-04-06, 2026-10-06, 2025-10-28) and updates the label to Last Update Posted (Estimated).SummaryDifference0.8%

- Check108 days agoChange DetectedUpdate includes a prominent operating-status notice and a version upgrade from v3.1.0 to v3.2.0. The core effect is informing users about possible delays and the current open status of the NIH Clinical Center.SummaryDifference3%

Stay in the know with updates to Nivolumab and Axitinib in RCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and Axitinib in RCC Clinical Trial page.